Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TR 700

Known as: TR-700 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
The in vitro activities of tedizolid and 10 antistaphylococcal agents were compared against 111 methicillin-resistant… Expand
Is this relevant?
2012
2012
OBJECTIVES To compare the activity of tedizolid (formally known as torezolid and TR-700) with that of 15 agents against a… Expand
  • table 1
  • table 2
Is this relevant?
2011
2011
Torezolid phosphate (TR-701) is the phosphate monoester prodrug of the oxazolidinone TR-700 which demonstrates potent in vitro… Expand
Is this relevant?
2010
2010
This study assessed the spectrum of activity of torezolid (TR-700), the active moiety of torezolid phosphate (TR-701), and… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
TR-701 is the prodrug of the microbiologically active molecule TR-700, a novel orally and intravenously administered… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
TR-700 (torezolid), the active moiety of the novel oxazolidinone phosphate prodrug TR-701, is highly potent against gram-positive… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND TR-700 is the active moiety of TR-701 (DA-7157), a new oral/intravenous oxazolidinone prodrug. We examined its… Expand
  • figure 1
  • table 1
Is this relevant?
2009
2009
BACKGROUND AND AIMS Optimal treatment of infections caused by Staphylococcus aureus, Listeria monocytogenes and Legionella… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2009
2009
BACKGROUND TR-700, the active component of the oxazolidinone prodrug TR-701, has demonstrated potent activity against numerous… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
TR-701 is the orally active prodrug of TR-700, a novel oxazolidinone that demonstrates four- to eightfold-greater activity than… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?